Work

High tumor mutational burden (TMB) and PD-L1 have similar predictive utility in 2L+ NSCLC patients (pts) treated with anti-PD-L1 and anti-CTLA-4

Year: 2018

Type: article

Abstract: Background: PD-L1 can predict benefit from anti-PD-1/L1 therapies; TMB is an emerging biomarker that may have additional predictive utility. We compared the utility of high TMB and PD-L1 to predict outcomes in NSCLC non-squamous pts treated with anti-PD-L1 (durvalumab) and anti-CTLA-4 monoclonal antibodies (tremelimumab, D+T).

Source: Annals of Oncology

DOI: 10.1093/annonc/mdy269.063

Authors: B.W. Higgs, C.A. Morehouse, P.Z. Brohawn, S. Sridhar, R. Raja, G. Gao, J. Englert, K. Ranade

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $5,080

OpenAlex ID: W2898522386

FWCI: 0.421

Cites:

Cited by: 5

Related to: 10